Recent advance in synergistic pathogenesis of complement and antibody in Guillain-Barré syndrome and its immunotherapy
10.3760/cma.j.cn115354-20250327-00175
- VernacularTitle:吉兰-巴雷综合征中补体与抗体协同致病机制及其免疫治疗的研究进展
- Author:
Yuqian XUE
1
;
Ailing LIU
;
Chengjing FEI
;
Yulei LIU
;
Minghao DU
;
Zeyu ZHANG
;
Rong YIN
Author Information
1. 甘肃中医药大学第一临床医学院，兰州 730000
- Publication Type:Journal Article
- Keywords:
Guillain-Barré syndrome;
Complement;
Antibody;
Immunotherapy;
Synergistic Pathogenesis
- From:
Chinese Journal of Neuromedicine
2025;24(9):959-964
- CountryChina
- Language:Chinese
-
Abstract:
Guillain-Barré syndrome (GBS) is an autoimmune-mediated acute polyradiculoneuropathy. Its key feature is focal segmental demyelination along with inflammatory cell infiltration and axonal damage. In clinical practice, anti-ganglioside antibodies in the body fluid of GBS patients show heterogeneity, and conventional immunotherapy is ineffective in some GBS subtypes. Drawing on treatment options for other neuroimmune diseases, targeted regulation of antibody-complement system has now become an important direction in GBS treatment research. This paper examines the immune response mechanisms involving complement, antibodies and related inflammatory factors, explores new strategy in GBS immunotherapy, so as to provide theoretical basis and research entry points for GBS individualized treatment.
